Suppr超能文献

一种可消融难治性、低生长分数肿瘤的抗癌治疗方法的临床前及临床验证

PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS.

作者信息

Sorscher Eric J, Hong Jeong S, Parker William B

机构信息

atlanta, georgia.

出版信息

Trans Am Clin Climatol Assoc. 2016;127:59-70.

Abstract

Intratumoral expression of the purine nucleoside phosphorylase (PNP) gene was originally described by our laboratories as a means to inhibit growth of solid tumors . The approach generates purine bases that disrupt DNA, RNA, and protein synthesis, a unique mechanism when compared with all approved or experimental cancer therapeutics. Use of PNP has been validated by numerous laboratories worldwide against human tumor xenografts (lung, liver, pancreas, bladder, glioma, and prostate, among others). Data from a recently completed phase 1 clinical trial has indicated substantial anti-cancer activity in human subjects with no serious toxicities.

摘要

我们实验室最初描述了嘌呤核苷磷酸化酶(PNP)基因在肿瘤内的表达,这是一种抑制实体瘤生长的方法。该方法产生的嘌呤碱会破坏DNA、RNA和蛋白质合成,与所有已批准或实验性癌症治疗方法相比,这是一种独特的机制。全球众多实验室已针对人肿瘤异种移植(包括肺癌、肝癌、胰腺癌、膀胱癌、神经胶质瘤和前列腺癌等)验证了PNP的用途。最近完成的一项1期临床试验的数据表明,该药物在人类受试者中具有显著的抗癌活性,且无严重毒性。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验